Use of the second cerebrotropic melanoma cell line, A375Br, yielded similar results; treatment with anti-VEGF alone or in combination with anti–PD-1 resulted in increased PBMC transwell migration (P = 0.0077 and 0.0079, respectively). The gene discussed is VEGFA; the disease is melanoma.